Black-Enochian-Primary-Logo.jpg
Enochian BioSciences Inventor and Co-Founder Presents Data on Novel Clinical Approaches as the Invited, Concluding Plenary Speaker at the Innate Killer Summit
April 05, 2022 06:00 ET | Enochian BioSciences, Inc.
LOS ANGELES, April 05, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene-modified cellular and immune therapies for infectious diseases and cancer, announced...
Cytovia.png
Cytovia Therapeutics’ Leadership to Present at Upcoming Conferences
March 29, 2022 10:56 ET | Cytovia Therapeutics
AVENTURA, Fla. and NATICK, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell...
CytoImmune Therapeutics Announces Publication Demonstrating Platelet-Derived Growth Factor D Signaling Activates Natural Killer (NK) Cells and Enhances NK Cell Survival
January 25, 2022 08:00 ET | CytoImmune Therapeutics
TOA BAJA, Puerto Rico, Jan. 25, 2022 (GLOBE NEWSWIRE) -- CytoImmune Therapeutics, a clinical-stage immunotherapy company that is developing a novel class of natural killer (NK) cell-based cancer...
Cytovia.png
Evelyn D’An Joins Cytovia Therapeutics as Chief Financial Officer
October 12, 2021 12:24 ET | Cytovia Therapeutics
AVENTURA, Fla., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc. (“Cytovia”), a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited iNK and CAR (Chimeric Antigen...
Cytovia.png
Cytovia Therapeutics and its Newly Formed China-Focused CytoLynx Joint Venture Raise $45 Million to Advance NK Cell Therapy Pipeline
September 13, 2021 10:08 ET | Cytovia Therapeutics
Cytovia eligible for up to $400 million in licensing milestones for Greater China rightsCoordinated US and China clinical development of GPC3-targeted therapies for hepatocellular carcinoma AVENTURA,...
Roots-Analysis-Logo.png
The global cell therapy packaging services market is projected to be worth USD 1.1 billion in 2030, growing at a CAGR of ~19%, claims Roots Analysis
August 04, 2021 08:45 ET | Roots Analysis
London, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Cell Therapy Packaging Products and Services Market, 2021-2030”report to its list of offerings. Currently,...
Cytovia.png
Olivier Gouédard, PharmD, MBA joins Cytovia Therapeutics as Chief Operating Officer
June 22, 2021 08:55 ET | Cytovia Therapeutics
CAMBRIDGE, Mass. and AVENTURA, Fla., June 22, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Chimeric Antigen...
Cytovia.png
William Sullivan, CPA, MBA joins Cytovia Therapeutics as Chief Financial Officer
June 15, 2021 13:21 ET | Cytovia Therapeutics
CAMBRIDGE, Mass. and AVENTURA, Fla., June 15, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Chimeric Antigen...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento and Researchers at Karolinska Institutet Have Signed a Research Collaboration Agreement on iPSC-Derived Dimeric Antigen Receptor-Modified Natural Killer (DAR-NK) Cells With The Vision to Bring “Off-The-Shelf" NK Cell-Based Cancer Treatments Rapidly to Patients
June 04, 2021 13:00 ET | Sorrento Therapeutics, Inc.
SAN DIEGO and STOCKHOLM, Sweden, June 04, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the Company has entered into an additional...
Teneo_logo_FINAL_whitebkgnd.png
Teneobio’s Clinical Candidate, TNB-409, is a Selective IL-2 Receptor Bispecific Agonist for the Treatment of Solid Tumors
May 19, 2021 08:00 ET | TeneoBio, Inc
NEWARK, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical stage biotech company focused on the discovery and development of novel multi-specific biotherapeutic antibodies,...